CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Summary

This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive).

Timeline

Start

2023-06-06

Primary completion

2026-04-30

Completion

2026-05-29

Outcome

Outcome not reported

Stopped: “IND application withdrawn”

Drugs

Indications